FGFR-IN-9
FGFR-IN-9 (Compound 19) is a potent, reversible and orally active FGFR inhibitor with an IC50 of 17.1, 29.6, 30.7, 46.7 and 64.3 nM against FGFR4WT, FGFR3, FGFR4V550L, FGFR2 and FGFR1, respectively.
For research use only. We do not sell to patients.
- CAS No.: 3024090-08-9
- Formula: C25H28N6O3S
- Molecular Weight:492.59
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
|
FGFR4WT 17.1 nM (IC50) |
FGFR3 29.6 nM (IC50) |
FGFR4V550L 30.7 nM (IC50) |
FGFR2 46.7 nM (IC50) |
FGFR1 64.3 nM (IC50) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| BaF3 | IC50 |
260 nM
Compound: 19
|
Cytotoxicity against mouse BaF3 cells expressing TEL-fused FGFR4 V550L mutant assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
Cytotoxicity against mouse BaF3 cells expressing TEL-fused FGFR4 V550L mutant assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
|
[PMID: 36480917] |
| BaF3 | IC50 |
82.5 nM
Compound: 19
|
Cytotoxicity against mouse BaF3 cells expressing wild type TEL-fused FGFR4 assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
Cytotoxicity against mouse BaF3 cells expressing wild type TEL-fused FGFR4 assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
|
[PMID: 36480917] |
| BaF3 | IC50 |
>2000 nM
Compound: 19
|
Cytotoxicity against mouse BaF3 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
Cytotoxicity against mouse BaF3 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
|
[PMID: 36480917] |
| Huh-7 | IC50 |
94.7 nM
Compound: 19
|
Cytotoxicity against human Huh-7 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter-Glo assay
Cytotoxicity against human Huh-7 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter-Glo assay
|
[PMID: 36480917] |
| KATO III stomach cancer cell line | IC50 |
6 nM
Compound: 19
|
Cytotoxicity against FGFR2-amplified human KATO III stomach cancer cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter-Glo assay
Cytotoxicity against FGFR2-amplified human KATO III stomach cancer cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter-Glo assay
|
[PMID: 36480917] |
| NCI-H1581 | IC50 |
24.6 nM
Compound: 19
|
Cytotoxicity against FGFR1-amplified human NCI-H1581 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter-Glo assay
Cytotoxicity against FGFR1-amplified human NCI-H1581 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter-Glo assay
|
[PMID: 36480917] |
FGFR-IN-9 (Compound 19) (0-2 mM; 72 h) inhibits HUH7 cells with an IC50 of 94.7 ± 28.6 nM, and inhibits proliferation with IC50s of 82.5 ± 19.2 nM and 260.0 ± 50.2 nM against Ba/F3 FGFR4WT and Ba/F3 FGFR4V550L cells, respectively[1].
FGFR-IN-9 (0-400 nM; 4 h) inhibits FGFR signaling pathway[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Ba/F3-TEL-FGFR4 cells
-
Concentration:0, 50, 100, 200 and 400 nM
-
Incubation Time:4 h
-
Result:Showed dose-dependent inhibition of the FGFR4 signal cassette, including the phosphorylation of FGFR4 and its downstream effectors FRS2 and PLCγ.
In Vivo Pharmacokinetic Profile Data for FGFR-IN-9 (Compound 19) [1]
| FGFR-IN-9 | i.v. 1 mg/kg | p.o. 10 mg/kg |
| T1/2 (h) | 1.3 | 2.37 |
| Tmax (h) | / | 2 |
| Cmax (ng/mL) | / | 202 |
| AUCmax (h·ng/mL) | 175 | 965 |
| AUCINF (h·ng/mL) | 177 | 1087 |
| MRTinf (h) | 1.13 | 3.87 |
| F (%) | / | 61.5 |
| VSS (L/kg) | 6.37 | / |
| CL (L/h/kg) | 5.65 | / |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female BALB/c nude mice, HUH7 xenograft model[1]
-
Dosage:30 and 45 mg/kg
-
Administration:Intragastric gavage; daily for 3 weeks
-
Result:Resulted in significant tumor growth inhibition with a TGI value of 81% and an IR value of 63% at a dose of 45 mg/kg. No significant body weight loss (<5%) was observed.
-
Animal Model:Male CD-1 mice[1]
-
Dosage:1 mg/kg and 10 mg/kg
-
Administration:i.v. and p.o. (Pharmacokinetic Analysis)
-
Result:Showed good in vivo pharmacokinetic profile.
Chemical Information
-
CAS No. 3024090-08-9
-
Molecular Weight 492.59
-
Formula C25H28N6O3S
-
SMILES
O=S(N1C=CC2=CN=C(NC3=CC=C(N4C[C@H](C)N[C@H](C)C4)C=C3)N=C21)(C5=CC=CC(OC)=C5)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)